Related Experiment Video

Updated: Aug 19, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

Biagio Ricciuti1, Alessia Mira2, Elisa Andrini3,4

  • 1Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Drugs in Context
|December 1, 2022
PubMed

Insights

Targeting KRAS G12C mutations in non-small cell lung cancer (NSCLC) offers new hope. This review covers current treatments, resistance mechanisms, and strategies for KRAS G12C-mutant NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Constitutive KRAS signaling is a key driver of tumorigenesis in various cancers.
  • Activating KRAS mutations, particularly KRAS G12C, are prevalent in approximately 30% of non-small cell lung cancer (NSCLC) cases.
  • KRAS mutations were historically considered undruggable targets for over four decades.

Purpose of the Study:

  • To review the current treatment landscape for advanced NSCLC with KRAS G12C mutations.
  • To explore emerging therapeutic strategies, including direct KRAS inhibitors and PD-(L)1-based therapies.
  • To investigate mechanisms of resistance to KRAS inhibition and potential overcoming strategies.

Main Methods:

  • Literature review of current treatment options for KRAS G12C-mutant NSCLC.
  • Analysis of clinical trial data and research on direct KRAS inhibitors.
  • Exploration of resistance pathways and combination therapies.

Main Results:

  • Allelic-specific KRAS inhibitors represent a significant advancement in personalized cancer medicine.
  • Current treatment options include PD-(L)1-based therapies and direct KRAS inhibitors.
  • Understanding resistance mechanisms is crucial for optimizing sequential treatment strategies.

Conclusions:

  • Targeted therapies for KRAS G12C-mutant NSCLC are transforming patient care.
  • Further research into overcoming resistance is essential for improving long-term outcomes.
  • Personalized medicine approaches are increasingly effective for NSCLC patients with specific KRAS alterations.
Keywords:
G12CKRASNSCLCimmunotherapysotorasib

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K